Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,130 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05703516 | A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea | recruiting | — | 44 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05933239 | Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients(MAGMA) | recruiting | Phase 2 | 20 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07617246 | The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer | recruiting | Phase 2 | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05679349 | Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking | recruiting | N/A | 822 | Ronald MyersOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05718323 | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC(RAISE) | recruiting | Phase 2 | 44 | ETOP IBCSG Partners FoundationNETWORK | 5 | May 29, 2026 | clinicaltrials |
| NCT05802186 | Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study | recruiting | N/A | 70 | Northwestern UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07612722 | Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo | recruiting | N/A | 585 | Wen-zhao ZHONGOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06566443 | Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer | recruiting | Phase 1 | 15 | The Methodist Hospital Research InstituteOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06843629 | Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors | recruiting | — | 100 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06869447 | New York Better Breathing Study | recruiting | N/A | 100 | Roswell Park Cancer InstituteOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07102147 | Telehealth Collaborative Care Model (CoCM) in Lung Cancer | recruiting | N/A | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07201194 | Holistic Acupuncture for Patients With Chemotherapy Induced Nausea | recruiting | N/A | 90 | Vejle HospitalOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07223047 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 252 | Bristol-Myers SquibbINDUSTRY | 3 | May 28, 2026 | clinicaltrials |
| NCT07610616 | Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids | recruiting | — | 10 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT03848052 | Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC) | recruiting | — | 75,000 | UNICANCEROTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT07608835 | IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy(IMMUNOLUNG) | recruiting | N/A | 200 | Institut Paoli-CalmettesOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT06974370 | Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial(ACTION-Brain) | recruiting | Phase 2 | 45 | University of Vermont Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07249372 | DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer | recruiting | Phase 2 | 37 | NYU Langone HealthOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07375316 | A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy | recruiting | Phase 2 | 120 | Guangdong Association of Clinical TrialsOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07584239 | Prehabilitation Physical Therapy and Relaxation Intervention Program to Promote Resiliency and Operative Success Among Adults Receiving Lung Cancer Surgery, ROAR-LCS Trial | recruiting | N/A | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03387865 | A Clinico-biological Database of Lung Cancers(Bio-lung) | recruiting | — | 500 | University Hospital, LilleOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05800587 | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | recruiting | Phase 2 | 280 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06868849 | A Study of JMT203 in Patients With Cancer Cachexia | recruiting | Phase 1 / Phase 2 | 307 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07412327 | Prospective Phase II Clinical Study of Stereotactic Body Proton Therapy (SBPT) for Lung Cancer | recruiting | N/A | 65 | Guangzhou Concord Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04086082 | Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging(MAGIK) | recruiting | N/A | 30 | University of SydneyOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06494254 | Post-Operative Prediction of PulmonarY Function(POPPY) | recruiting | — | 15 | University of SydneyOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06844344 | Diagnosing peRipheral Lung Lesions With CRYO Biopsies(DR CRYO) | recruiting | N/A | 100 | Odense University HospitalOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05030207 | Respiratory Adaptive Computed Tomography: Feasibility Study on Real-Time Gated 4DCT for Lung Cancer Radiotherapy(REACT) | recruiting | N/A | 30 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05431270 | Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | recruiting | Phase 1 / Phase 2 | 40 | Phanes TherapeuticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT06127654 | Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy(VITaL) | recruiting | Phase 3 | 165 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07154706 | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) | recruiting | Phase 3 | 180 | Nuvation Bio Inc.INDUSTRY | 3 | May 19, 2026 | clinicaltrials |
| NCT07596121 | Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50% | recruiting | Phase 2 | 60 | Tang-Du HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03851445 | Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 10,000 | SWOG Cancer Research NetworkNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT04067830 | Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer | recruiting | Phase 2 | 220 | Roswell Park Cancer InstituteOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05885698 | MYLUNG Consortium Part 3: Observational Study(MYLUNG) | recruiting | — | 7,500 | US Oncology ResearchINDUSTRY | 1 | May 18, 2026 | clinicaltrials |
| NCT06431633 | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.(ARIAN) | recruiting | Phase 3 | 129 | Fundación GECPOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06868836 | Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy | recruiting | Phase 2 | 78 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07094204 | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | recruiting | Phase 1 | 364 | Astellas Pharma IncINDUSTRY | 4 | May 18, 2026 | clinicaltrials |
| NCT07309276 | A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer | recruiting | Phase 2 | 864 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07394062 | Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)(ALCG-01) | recruiting | — | 400 | Gazi UniversityOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07594522 | A Study of Ivonescimab in People With Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05724264 | SingapOre Lung Cancer Screening Through Integrating CT With Other biomarkErs (SOLSTICE) | recruiting | N/A | 1,000 | National Cancer Centre, SingaporeOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07332858 | First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion | recruiting | Phase 1 / Phase 2 | 105 | Gang HouOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07591389 | Promoting Radon Testing Among Mothers of Young Children | recruiting | N/A | 100 | University of North DakotaOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04789486 | Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06284317 | A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.(ADOPT-lung) | recruiting | Phase 3 | 290 | ETOP IBCSG Partners FoundationNETWORK | 10 | May 14, 2026 | clinicaltrials |
| NCT06417814 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(TROPION-Lung15) | recruiting | Phase 3 | 744 | AstraZenecaINDUSTRY | 27 | May 14, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 1, 2026source: clinicaltrials